A Phase II Study of Avelumab in Patients With Mismatch Repair Deficient or POLE Mutated Metastatic Colorectal Cancer
Latest Information Update: 08 Apr 2022
At a glance
- Drugs Avelumab (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- 01 Apr 2020 Planned primary completion date changed from 31 Dec 2020 to 31 Jul 2021.
- 14 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 21 Feb 2018 Planned End Date changed from 1 Dec 2019 to 31 Dec 2021.